PPT-≥ 18 years HCV genotype 1, 2, 4, 5, 6

Author : alexa-scheidler | Published Date : 2018-02-06

HCV RNA 1000 IUmL Treatmentnaïve or treatmentexperienced with IFN or PEGIFN RBV or SOF RBV PEGIFN Compensated cirrhosis No HBV or HIV coinfection Design

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "≥ 18 years HCV genotype 1, 2, 4, 5, 6" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

≥ 18 years HCV genotype 1, 2, 4, 5, 6: Transcript

HCV RNA 1000 IUmL Treatmentnaïve or treatmentexperienced with IFN or PEGIFN RBV or SOF RBV PEGIFN Compensated cirrhosis No HBV or HIV coinfection Design W12 EXPEDITION1 . Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. Warren W. . Kretzschmar. DPhil Genomic Medicine and Statistics. Wellcome. Trust Centre for Human . Genetics, Oxford. , UK . Supervisor: Jonathan . Marchini. C. ommonest . psychiatric disorder and the second ranking cause of morbidity world-. OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open label. 18-70 years. Chronic HCV infection. Genotype 4 . Treatment-naïve or failure . t. o PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis**. No HBV or HIV co-infection. ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. Markov Models of Haplotype Diversity. Justin Kennedy. Dissertation . Defense for . the Degree of Doctorate in Philosophy. Computer Science & Engineering Department. University of Connecticut. 1. Outline. siemens.com/molecular Optimize Treatment Decisions with Universal Genotyping Technology Optimize your laboratory’s testing with the leading, most widely used HCV-genotyping technology available&# ,. F.I.B.M.S;. MPhil. (. Mol.Bio. ). PhD (Human Genetics & . Mol.Bio. ). Personal Information. Personal Detail. Name : . Ghazala. . Rubi. . email. rubighazala@yahoo.com. Nationality : Pakistani. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. Global epidemiology of hepatitis C virus infection: . New estimates of age‐specific antibody to HCV seroprevalence. Mohd. . Hanafiah. , K. . et al.57 (4) . Hepatology. , 2013. HCV Epidemiology in West Africa. Hansen Dang,. 1,2*. Yee Hui Yeo,. 1*. Satoshi Yasuda,. 3. Chung-Feng Huang,. 4. Etsuko Iio,. 5. Charles Landis,. 6. Dae Won Jun,. 7. Masaru Enomoto,. 8. Eiichi Ogawa,. 9. Pei-. Chien. Tsai,. & . Update on HCV . blood bank protocol. . Overview - . diagnostic tests. Serologic . assays: . specific antibody to hepatitis C virus (anti-HCV). Molecular . assays: HCV nucleic acid . (. nucleic. Non . inferiority. of SOF + RBV : SVR. 12. (. 2-sided significance level of 5%, . lower margin of the . 95% CI for the difference = -15%, 95% power). SOF + RBV (weight based). PEG-IFN. a. -2a + RBV (fixed-dose).

Download Document

Here is the link to download the presentation.
"≥ 18 years HCV genotype 1, 2, 4, 5, 6"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.